title: Blinatumomab: A New Treatment for Adults With Relapsed Acute Lymphocytic Leukemia.
abstract: BACKGROUND
  Patients with acute lymphocytic leukemia (ALL) often experience relapse of their disease following standard treatment. Blinatumomab (Blincyto®) is a newly approved option for inducing remission in individuals with relapsed or refractory Philadelphia chromosome-negative B-cell ALL.
  
  
  OBJECTIVE
  This article provides an overview of blinatumomab, its benefits demonstrated in clinical trials, adverse effects, administration details, and the role of the oncology nurse in caring for and educating patients who receive blinatumomab.
  
  
  METHODS
  This article summarizes the results of two phase II studies on blinatumomab and provides practice implications for nurses caring for patients receiving this therapy.
  
  
  RESULTS
  Attentive symptom monitoring and management are crucial. Individuals who achieve remission from blinatumomab can then be considered for stem cell transplantation and a chance for cure.
authors.affiliation: Texas Oncology.
authors.forename: Jessica
authors.initials: J
authors.lastname: Turner
authors.affiliation: School of Nursing, Duke University, Durham, NC.
authors.forename: Susan M
authors.initials: SM
authors.lastname: Schneider
mesh_terms: D000328:Adult; D018033:Antibodies, Bispecific / Q000008:administration & dosage*; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017277:Drug Approval; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009859:Oncology Nursing / Q000379:methods; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000451:nursing*; D012008:Recurrence; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D018033:Antibodies, Bispecific; C510808:blinatumomab
keywords: biotherapy; clinical trials; hematology; leukemia; lymphoma; targeted therapies